Omeprazole activates aryl hydrocarbon receptor to reduce hyperoxia-induced oxidative stress in the peripheral blood mononuclear cells from premature infants

Abstract Objective To investigate the correlation between the aryl hydrocarbon receptor (AhR) and reactive oxygen species (ROS) in peripheral blood mononuclear cells (PBMCs) of premature infants, to demonstrate the protective role of AhR against hyperoxia-induced oxidative stress in premature infants and to provide a rational basis for the use of omeprazole (OM) as a new treatment for bronchopulmonary dysplasia (BPD). Methods From January 2021 to June 2021, 1–3 ml of discarded peripheral blood was collected from premature infants of gestational age less than 32 weeks who were not taking inhaled oxygen and were admitted to the Department of Neonatology of the Affiliated Hospital of Southwest Medical University. Using a random number table, the PBMCs were randomly assigned to each of the following groups: the control group, air + OM group, hyperoxia group, and hyperoxia + OM group. After 48 h of in vitro modeling and culture, PBMCs and the culture medium of each group were collected. Immunofluorescence analysis was used to examine ROS levels in PBMCs. A full-spectrum spectrophotometer was used to examine malondialdehyde (MDA) levels in the culture medium. Enzyme-linked immunosorbent assay (ELISA) was used to examine monocyte chemotactic protein 1 (MCP-1) levels in culture medium. Immunofluorescence analysis was used to examine the intracellular localization of AhR. Western blotting was used to examine the expression level of AhR in PBMCs. Results Compared with those in the control group, the levels of ROS, MDA, and MCP-1 and the cytoplasm-nuclear translocation rate of AhR in the air + OM group did not change significantly (p > 0.05), but the expression level of AhR increased significantly (p < 0.05). The levels of ROS, MDA, and MCP-1 and the cytoplasm-nuclear translocation rate of AhR significantly increased in the hyperoxia group (p < 0.05), and the expression level of AhR was significantly reduced (p < 0.05). Compared with those in the hyperoxia group, the levels of ROS, MDA, and MCP-1 in the hyperoxia + OM group were significantly reduced (p < 0.05), and the cytoplasm-nuclear translocation rate of AhR and the expression level of AhR were significantly increased (p < 0.05), but did not reach the level of the control group (p < 0.05). Conclusion OM can activate AhR to inhibit hyperoxia-induced oxidative stress in the PBMCs from premature infants.

[1]  J. Pillow,et al.  Enteral Vitamin A for Reducing Severity of Bronchopulmonary Dysplasia: A Randomized Trial , 2021, Pediatrics.

[2]  Wenbin Dong,et al.  Protective effects of resveratrol on hyperoxia-induced lung injury in neonatal rats by alleviating apoptosis and ROS production , 2020, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[3]  M. Usami,et al.  Inhibitory and inductive effects of 4- or 5-methyl-2-mercaptobenzimidazole, thyrotoxic and hepatotoxic rubber antioxidants, on several forms of cytochrome P450 in primary cultured rat and human hepatocytes , 2020, Toxicology reports.

[4]  G. Hansmann,et al.  Pulmonary hypertension in bronchopulmonary dysplasia , 2020, Pediatric Research.

[5]  Z. Rahman,et al.  Ethanol-induced gastric ulcer in rats and intervention of tert-butylhydroquinone: Involvement of Nrf2/HO-1 signalling pathway , 2019, Human & experimental toxicology.

[6]  Yue Dai,et al.  Therapeutic potential of aryl hydrocarbon receptor ligands derived from natural products in rheumatoid arthritis. , 2019, Basic & clinical pharmacology & toxicology.

[7]  M. Furue,et al.  Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis , 2019, International journal of molecular sciences.

[8]  R. Higgins Oxygen Saturation and Retinopathy of Prematurity. , 2019, Clinics in perinatology.

[9]  A. Badr,et al.  The implication of the crosstalk of Nrf2 with NOXs, and HMGB1 in ethanol-induced gastric ulcer: Potential protective effect is afforded by Raspberry Ketone , 2019, PloS one.

[10]  F. Polack,et al.  The discovery BPD (D-BPD) program: study protocol of a prospective translational multicenter collaborative study to investigate determinants of chronic lung disease in very low birth weight infants , 2019, BMC Pediatrics.

[11]  E. Baraldi,et al.  Update on Postnatal Corticosteroids to Prevent or Treat Bronchopulmonary Dysplasia , 2019, American Journal of Perinatology.

[12]  Weiming Zhao,et al.  Caffeine Inhibits NLRP3 Inflammasome Activation by Suppressing MAPK/NF-κB and A2aR Signaling in LPS-Induced THP-1 Macrophages , 2019, International journal of biological sciences.

[13]  J. Pillow,et al.  Bronchopulmonary dysplasia: Pathophysiology and potential anti-inflammatory therapies. , 2019, Paediatric respiratory reviews.

[14]  Chandragouda R. Patil,et al.  Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in Wistar rats , 2019, Molecular and Cellular Biochemistry.

[15]  Wenbin Dong,et al.  Oxidative stress and bronchopulmonary dysplasia. , 2018, Gene.

[16]  R. Savani Modulators of inflammation in Bronchopulmonary Dysplasia. , 2018, Seminars in perinatology.

[17]  Li Luo,et al.  Aryl Hydrocarbon Receptor Promotes IL-10 Expression in Inflammatory Macrophages Through Src-STAT3 Signaling Pathway , 2018, Front. Immunol..

[18]  Q. Lv,et al.  Cardamonin, a natural flavone, alleviates inflammatory bowel disease by the inhibition of NLRP3 inflammasome activation via an AhR/Nrf2/NQO1 pathway , 2018, Biochemical pharmacology.

[19]  Xiaoping Lei,et al.  Resveratrol suppresses hyperoxia-induced nucleocytoplasmic shuttling of SIRT1 and ROS production in PBMC from preterm infants in vitro , 2018, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[20]  A. Jobe Mechanisms of Lung Injury and Bronchopulmonary Dysplasia , 2016, American Journal of Perinatology.

[21]  J. Deprest,et al.  Proton-pump inhibitor omeprazole attenuates hyperoxia induced lung injury , 2016, Journal of Translational Medicine.

[22]  M. Geffard,et al.  Aryl hydrocarbon receptor control of a disease tolerance defence pathway , 2014, Nature.

[23]  F. Quintana,et al.  Aryl Hydrocarbon Receptor Control of Adaptive Immunity , 2013, Pharmacological Reviews.

[24]  M. Nagarkatti,et al.  Use of natural AhR ligands as potential therapeutic modalities against inflammatory disorders. , 2013, Nutrition reviews.

[25]  S. Welty,et al.  Omeprazole attenuates hyperoxic injury in H441 cells via the aryl hydrocarbon receptor. , 2011, Free radical biology & medicine.

[26]  P. Mcgeer,et al.  Proton pump inhibitors reduce interferon‐γ‐induced neurotoxicity and STAT3 phosphorylation of human astrocytes , 2011, Glia.

[27]  Y. Fujii‐Kuriyama,et al.  Molecular mechanisms of the physiological functions of the aryl hydrocarbon (dioxin) receptor, a multifunctional regulator that senses and responds to environmental stimuli , 2010, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[28]  A. Jaiswal,et al.  Persistent induction of hepatic and pulmonary phase II enzymes by 3-methylcholanthrene in rats. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[29]  T. Thatcher,et al.  Aryl Hydrocarbon Receptor-Deficient Mice Develop Heightened Inflammatory Responses to Cigarette Smoke and Endotoxin Associated with Rapid Loss of the Nuclear Factor-κB Component RelB , 2007 .

[30]  G. Perdew,et al.  Characterization of the AhR-hsp90-XAP2 core complex and the role of the immunophilin-related protein XAP2 in AhR stabilization. , 1999, Biochemistry.

[31]  Jan Kremláček,et al.  Serum Levels of Aryl Hydrocarbon Receptor, Cytochromes P450 1A1 and 1B1 in Patients with Exacerbated Psoriasis Vulgaris. , 2018, Folia biologica.

[32]  C. Day,et al.  Bronchopulmonary dysplasia: new becomes old again! , 2017, Pediatric Research.

[33]  T. Yeh,et al.  Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia. , 2016, American journal of respiratory and critical care medicine.

[34]  T. Thatcher,et al.  Aryl hydrocarbon receptor-deficient mice develop heightened inflammatory responses to cigarette smoke and endotoxin associated with rapid loss of the nuclear factor-kappaB component RelB. , 2007, The American journal of pathology.

[35]  L. Monte,et al.  [Bronchopulmonary dysplasia]. , 2005, Jornal de pediatria.